Shao-Lee Lin, Acelyrin CEO
Acelyrin tops its $250M crossover with new $300M cash raise from blue-chip syndicate
Shao-Lee Lin and her LA-based team at Acelyrin are back — and bringing its largest financing haul yet.
The biotech reported a $300 million Series C …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
